ONWARD THERAPEUTICS
Onward Therapeutics is a development-stage oncology company, focusing on the identification and development of innovative medicines for the treatment of cancer. The company, led by an experienced team in drug development, adopts a 'Buy and Build' business model of acquiring licenses for potential development candidates and investing in their partners with platform technologies.
Similar Organizations
Immodulon Therapeutics Ltd.
Immodulon Therapeutics Ltd. is a privately-owned immuno-oncology company
Isarna Therapeutics
Isarna Therapeutics is a biotechnology company.
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2022-06-17 | EMERCell | EMERCell acquired by Onward Therapeutics | N/A |
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-02-17 | EMERCell | Onward Therapeutics investment in Corporate Round - EMERCell | N/A |
More informations about "Onward Therapeutics"
Onward Therapeutics 2025 Company Profile: Valuation, Funding ...
Information on valuation, funding, cap tables, investors, and executives for Onward Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Onward Therapeutics - Crunchbase Investor Profile & Investments
Onward Therapeutics is a development-stage oncology company, focusing on the identification and development of innovative medicines for the treatment of cancer.See details»
Onward Therapeutics Announces IMPD Approval for Its
Apr 22, 2025 /CNW/ -- Onward Therapeutics SA, a biotechnology company dedicated to advancing innovative cancer immunotherapies, announced that its subsidiary, Emercell SAS,...See details»
Onward Therapeutics SA - Swiss Biotech
We are a development stage oncology company, focusing on the identification of innovative technologies and the development of truly breakthrough medicines for the treatment of cancer.See details»
Onward Therapeutics - VentureRadar
Onward Therapeutics is a development stage oncology company, focusing on the identification of innovative technologies and the development of truly breakthrough medicines for the treatment โฆSee details»
C. Grace Yeh, Ph.D. - ๅฐ็ฃๅฅณ่ฃไบๅๆ
Apr 25, 2023 Vice Chairman, Taiwan Bio Industry Organization / Chairman and CEO, Onward Therapeutics SA Dr. C. Grace Yeh is Chairman and CEO of Onward Therapeutics SA, a โฆSee details»
Grace Yeh Bio - Onward Therapeutics
Grace is one of the three founders, CEO and Chairman of Onward Therapeutics SA. Currently, she is on the board of Biomunex Pharmaceuticals SAS and EMERCell SAS. She also serves as Vice Chairman, Taiwan Biotechnology โฆSee details»
NEWS & EVENTS - Onward Therapeutics
NEWS & EVENTS Apr 22, 2025 Onward Therapeutics Announces IMPD Approval for Its Subsidiary Emercell to Start Clinical Investigation of Allogeneic NK Cell Therapy OT-C001 in โฆSee details»
PARTNERSHIPS | Onward Therapeutics
Partnering structure : Strategic equity investment Onward is the majority shareholder Onward works in collaboration with EMERCell who have developed generic cell immunotherapy โฆSee details»
ABOUT US | Onward Therapeutics
We are a development stage oncology company, focusing on the identification of innovative technologies and the development of truly breakthrough medicines for the treatment of cancer Our company, led by an experienced team in โฆSee details»
PowerPoint ็ฐกๅ ฑ - Swiss Medtech
Chairman and CEO, Onward Therapeutics SA Vice Chairman,Taiwan Bio Industry Organization (Taiwan BIO) Laureate, Industrial Technology Research Institute (ITRI)See details»
Onward Therapeutics' cancer immunotherapy enters clinical phase
Jan 30, 2024 Onward Therapeuticsโ move marks a critical transition for the company into the clinical stage, solidifying its role in developing innovative cancer treatments.See details»
Onward Therapeutics Signs an Exclusive Collaboration and โฆ
Jun 8, 2021 Onward Therapeutics SA is a development stage oncology company, focusing on the identification of innovative technologies and the development of truly breakthrough โฆSee details»
Onward - Crunchbase Company Profile & Funding
. When was the last funding round for Onward? Onward closed its last funding round on Nov 19, 2024 from a Grant round. Who are Onward's competitors? Alternatives and possible โฆSee details»
Onward Therapeutics Announces IMPD Approval for Its Subsidiary โฆ
Apr 22, 2025 Headquartered in Switzerland, Onward Therapeutics also operates in Paris and Taipei. About Emercell Emercell (www.emercell.com) develops off-the-shelf allogeneic NK cell โฆSee details»
Alain Herrera Bio - Onward Therapeutics
Alain is an MD trained in Oncology and Hematology. He founded, in 2020, with Grace Yeh and Armand de Gramont, Onward Therapeutics SA, bringing over 35 years of experience in clinical โฆSee details»
onward-therapeutics.com Reviews: Is this site a scam or legit?
Is onward-therapeutics.com legit or a scam? Read reviews, company details, technical analysis, and more to help you decide if this site is trustworthy or fraudulent.See details»
Grace Yeh - Emercell
Grace is one of the three founders, CEO and Chairman of Onward Therapeutics SA. Currently, she is on the board of Biomunex Pharmaceuticals SAS and EMERCell SAS. She also serves โฆSee details»
Onward Therapeutics Announces Enrollment of Phase 1 Clinical โฆ
Jan 24, 2024 Onward Therapeutics licensed the exclusive worldwide rights of development, manufacture, and commercialization of OT-A201 from Biomunex Pharmaceuticals (Biomunex), โฆSee details»
ONWARD Medical Adds Entrepreneur and Neurotechnology โฆ
3 days ago ONWARD Medical is the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and โฆSee details»